Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, und… Read more
Alx Oncology Holdings (ALXO) - Total Assets
Latest total assets as of September 2025: $82.72 Million USD
Based on the latest financial reports, Alx Oncology Holdings (ALXO) holds total assets worth $82.72 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Alx Oncology Holdings - Total Assets Trend (2018–2024)
This chart illustrates how Alx Oncology Holdings ’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Alx Oncology Holdings - Asset Composition Analysis
Current Asset Composition (December 2024)
Alx Oncology Holdings 's total assets of $82.72 Million consist of 90.9% current assets and 9.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.9% |
| Accounts Receivable | $892.00K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Alx Oncology Holdings 's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alx Oncology Holdings 's current assets represent 90.9% of total assets in 2024, a decrease from 91.4% in 2018.
- Cash Position: Cash and equivalents constituted 11.9% of total assets in 2024, down from 74.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Alx Oncology Holdings Competitors by Total Assets
Key competitors of Alx Oncology Holdings based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Alx Oncology Holdings - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Alx Oncology Holdings generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Alx Oncology Holdings is currently not profitable relative to its asset base.
Alx Oncology Holdings - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.40 | 4.82 | 70.28 |
| Quick Ratio | 2.40 | 4.82 | 70.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $38.79 Million | $ 123.56 Million | $ 429.79 Million |
Alx Oncology Holdings - Advanced Valuation Insights
This section examines the relationship between Alx Oncology Holdings 's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.49 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -39.1% |
| Total Assets | $147.78 Million |
| Market Capitalization | $27.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Alx Oncology Holdings 's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Alx Oncology Holdings 's assets decreased by 39.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Alx Oncology Holdings (2018–2024)
The table below shows the annual total assets of Alx Oncology Holdings from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $147.78 Million | -39.08% |
| 2023-12-31 | $242.55 Million | -20.86% |
| 2022-12-31 | $306.49 Million | -19.38% |
| 2021-12-31 | $380.18 Million | -12.81% |
| 2020-12-31 | $436.05 Million | +3984.43% |
| 2019-12-31 | $10.68 Million | -4.37% |
| 2018-12-31 | $11.16 Million | -- |